180 related articles for article (PubMed ID: 25351173)
41. Comparison of seed loading approaches in prostate brachytherapy.
Butler WM; Merrick GS; Lief JH; Dorsey AT
Med Phys; 2000 Feb; 27(2):381-92. PubMed ID: 10718143
[TBL] [Abstract][Full Text] [Related]
42. Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M; Shigematsu N; Kubo A
Brachytherapy; 2007; 6(4):246-53. PubMed ID: 17959425
[TBL] [Abstract][Full Text] [Related]
43. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
44. Dosimetric outcomes of preoperative treatment planning with intraoperative optimization using stranded seeds in prostate brachytherapy.
Lee JJB; Lee E; Choi WH; Kim J; Chang KH; Kim DW; Shin HB; Kim TH; Byun HK; Cho J
PLoS One; 2022; 17(3):e0265143. PubMed ID: 35353847
[TBL] [Abstract][Full Text] [Related]
45. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
46. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
47. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707
[TBL] [Abstract][Full Text] [Related]
48. The retrospective analysis of the relationship between prescribed dose and risk factor for seed migration in iodine-125 prostate brachytherapy.
Hirose K; Aoki M; Sato M; Akimoto H; Hashimoto Y; Imai A; Kamimura N; Kawaguchi H; Hatayama Y; Fujioka I; Tanaka M; Ohyama C; Takai Y
Jpn J Radiol; 2016 Nov; 34(11):718-723. PubMed ID: 27631882
[TBL] [Abstract][Full Text] [Related]
49. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study.
Charra-Brunaud C; Harter V; Delannes M; Haie-Meder C; Quetin P; Kerr C; Castelain B; Thomas L; Peiffert D
Radiother Oncol; 2012 Jun; 103(3):305-13. PubMed ID: 22633469
[TBL] [Abstract][Full Text] [Related]
50. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
Crook J; Ots A; Gaztañaga M; Schmid M; Araujo C; Hilts M; Batchelar D; Parker B; Bachand F; Milette MP
Brachytherapy; 2014; 13(5):433-41. PubMed ID: 24958556
[TBL] [Abstract][Full Text] [Related]
51. Quantifying the effect of seed orientation in postplanning dosimetry of low-dose-rate prostate brachytherapy.
Collins Fekete CA; Plamondon M; Martin AG; Vigneault É; Verhaegen F; Beaulieu L
Med Phys; 2014 Oct; 41(10):101704. PubMed ID: 25281943
[TBL] [Abstract][Full Text] [Related]
52. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
[TBL] [Abstract][Full Text] [Related]
53. Proposal of a post-prostatectomy clinical target volume based on pre-operative MRI: volumetric and dosimetric comparison to the RTOG guidelines.
Croke J; Maclean J; Nyiri B; Li Y; Malone K; Avruch L; Kayser C; Malone S
Radiat Oncol; 2014 Dec; 9():303. PubMed ID: 25534278
[TBL] [Abstract][Full Text] [Related]
54. Comparison between high and low source activity seeds for I-125 permanent seed prostate brachytherapy.
Masucci GL; Donath D; Tétreault-Laflamme A; Carrier JF; Hervieux Y; Larouche RX; Bahary JP; Taussky D
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):781-6. PubMed ID: 20171808
[TBL] [Abstract][Full Text] [Related]
55. Tissue composition and density impact on the clinical parameters for (125)I prostate implants dosimetry.
Oliveira SM; Teixeira NJ; Fernandes L; Teles P; Vieira G; Vaz P
Phys Med; 2014 Nov; 30(7):799-808. PubMed ID: 25239870
[TBL] [Abstract][Full Text] [Related]
56. Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: a prospective comparative toxicity analysis.
Gaudet M; Vigneault E; Aubin S; Varfalvy N; Harel F; Beaulieu L; Martin AG
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):153-9. PubMed ID: 19665322
[TBL] [Abstract][Full Text] [Related]
57. [Prostate cancer boost using high-dose-rate brachytherapy: impact of the learning curve on the dosimetry].
Benhaïm C; Chand MÈ; Gal J; Hijazi H; Gautier M; Hannoun-Lévi JM
Cancer Radiother; 2014 Nov; 18(7):659-65. PubMed ID: 25176296
[TBL] [Abstract][Full Text] [Related]
58. Prostate deformation from inflatable rectal probe cover and dosimetric effects in prostate seed implant brachytherapy.
Lian J; Shao Y; Potter LD; Chen RC; Holmes JA; Pryser EA; Shen J; Shen D; Wang AZ
Med Phys; 2016 Dec; 43(12):6569. PubMed ID: 27908182
[TBL] [Abstract][Full Text] [Related]
59. Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.
Veccia A; Caffo O; Fellin G; Mussari S; Ziglio F; Maines F; Tomio L; Galligioni E
Radiat Oncol; 2015 Jun; 10():130. PubMed ID: 26054532
[TBL] [Abstract][Full Text] [Related]
60. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy.
Salembier C; Lavagnini P; Nickers P; Mangili P; Rijnders A; Polo A; Venselaar J; Hoskin P;
Radiother Oncol; 2007 Apr; 83(1):3-10. PubMed ID: 17321620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
